A simple blood test may soon be helpful in predicting rheumatoid arthritis even before symptoms arise according to researchers. Rheumatoid arthritis is a chronic autoimmune disease characterized by joint inflammation involving the synovial (lubricating fluid of the joints) tissue and eventually leading to destruction of cartilage and bone. A research team from University Hospital in Umea, Sweden, have identified several cytokines, cytokine-related factors, and chemokines that increase significantly prior to rheumatoid arthritis (RA) disease onset. Led by Dr Solbritt Rantapaa-Dahlqvist, researchers sought to determine cytokines, cytokine-related factors, and chemokines are up-regulated prior to the development of rheumatoid arthritis. Blood samples of 86 individuals were analysed before the appearance of symptoms of RA. The study showed blood samples obtained from individuals had elevated concentrations of proinflammatory cytokines, cytokine-related factors, and chemokines, indicating immune system activation prior to any symptoms of joint involvement. The findings present an opportunity for better predicting the risk of developing RA and possibly preventing disease progression. An early and accurate diagnosis of RA is crucial. Studies have shown that people who receive early treatment for RA feel better sooner and more often, are more likely to lead an active life, and are less likely to experience the type of joint damage that leads to joint replacement. Be a part of Elets Collaborative Initiatives. Join Us for
Upcoming Events and explore business opportunities. Like us on
Facebook , connect with us on
LinkedIn and follow us on
Twitter ,
Instagram. "Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here! 
Related Pharma
Neuland Labs Q2 FY27 Profit Falls 47% as Margins Narrow
Hyderabad-based Neuland Laboratories Limited reported a 47% year-on-year fall in standalone profit after tax to ₹51.1 ...
Granules India Q2 FY27 Profit Rises 39% to ₹182 Crore
Hyderabad-based Granules India Limited reported a 39% year-on-year rise in consolidated net profit to ₹182 crore for t...
Lupin Gets USFDA Approval for Generic Amifampridine Tablets
Lupin Limited has received final approval from the United States Food and Drug Administration (USFDA) for its generic Am...
Court Discharges Ex-Drug Controller Eswara Reddy in Bribery Case
A special Central Bureau of Investigation (CBI) court at Rouse Avenue, New Delhi, on 31 October 2026 discharged Dr S. Es...
Emcure Q2 FY27 Profit Rises 29% as Overseas Sales Jump 35%
Emcure Pharmaceuticals Limited, the Pune-based drugmaker, reported on 3 November 2026 that its consolidated profit after...
AstraZeneca Gets Delhi HC Relief in ₹151 Crore NPPA Inhaler Case
AstraZeneca Pharma India Limited said on 2 November 2026 that the Delhi High Court has directed the National Pharmaceuti...
Gland Pharma Wins USFDA Nod for Generic Depo-Medrol Injection
Gland Pharma Limited, the Hyderabad-based generic injectables maker, said on 3 November 2026 that the US Food and Drug A...
Dr Reddy's Gets USFDA Tentative Nod for Generic Lenacapavir
Dr Reddy's Laboratories has received tentative approval from the US Food and Drug Administration (USFDA) for its generic...
Akums Q2 FY27 Profit Jumps 168% as CDMO Revenue Rises 39%
Akums Drugs and Pharmaceuticals, which describes itself as India's largest contract development and manufacturing organi...
Wockhardt Widens Miqnaf Access as Q2 Revenue Rises 24%
Wockhardt has widened access to its novel antibiotic Miqnaf (nafithromycin) in India after the Drugs Controller General ...